

## **Head of Translational Science, Redx Pharma**

Redx Pharma plc is an exciting biotech company focused on developing novel precision medicines that have the potential to transform treatment in oncology and fibrosis. Redx develops and manufactures small molecule treatments using its world-class medicinal chemistry expertise and lab infrastructure based at Alderley Park, Cheshire UK (former AstraZeneca R&D facility). This is combined with a deep understanding of the biology underlying diseases with high unmet medical need.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its three wholly-owned clinical-stage product candidates, namely RXC004, RXC007 and RXC008 and rapidly expanding preclinical pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a preclinical pan-RAF inhibitor, which has received IND clearance from the US FDA and an early stage oncology research collaboration.

### **The Role:**

Redx requires a highly experienced Translational Scientist and leader who provides scientific, project and strategic leadership for the translational studies allowing a seamless transition of drug candidates from discovery phase to clinical development. Specifically, this individual will be responsible for delivery of translational activities for all current wholly owned clinical assets in oncology and fibrosis. RXC004, a porcupine inhibitor is currently in Phase 2 trials in CRC, pancreatic and Biliary cancer, RXC007, a ROCK2 selective inhibitor planned to enter a Phase 2 clinical trial in IPF during 2022 and RXC008 currently undergoing IND enabling studies prior to entering a Phase 1 clinical trial in 2023.

### **Responsibilities include:**

- Providing expert opinions on all aspects of translational research relevant to drug discovery in the areas of Oncology and Inflammation/Fibrosis.
- Act as translational science leader to provide biomarker strategy on multiple drug discovery projects providing scientific direction and leadership to teams, where appropriate.
- Maintain awareness of regulatory environment in both US and Europe and worldwide to aid translational science objectives. Highlight any changes in the regulatory environment that could impact current or future projects.
- Coordinate with the CSO and wider R&D team to prioritise and develop workstreams, plan budgets, headcount, timelines and deliverables on the key projects ongoing within the translational science and lab teams.
- Creation of a Translational Science Plan and ensure delivery of translational project milestones in accordance with the project development plan.

- Responsibility for validation of biomarkers either through managing relationships with CROs or via delivery from in house Redx laboratory teams. May be required to directly line manage some of these individuals dependent on your previous experience and location.
- Lead development of the clinical lab manual and input to clinical protocols to ensure translational science objectives are met; data analysis and interpretation.
- Oversee the process of sample shipment and tracking of onsite human samples.
- Lead the prioritisation exercise for sample procurement and use in different assays.
- Represent translational science to potential collaborators/partners as required by Business Development.
- Contribute to the development of the whole of Redx as a high-quality research and development organisation.
- Undertake such academic, administrative and managerial duties that could be reasonably expected of a Head of Department as required by the Executive management, in particular COO and CSO.

**The successful candidate will:**

- Preferred candidates will have >15 years pharmaceutical and or biotech company experience in a senior translational science role in the oncology and or inflammation/fibrosis field.
- Have demonstrated evidence and knowledge of delivery of target engagement/proof of mechanism assays for use in early clinical trials to support dose selection.
- Have an in depth understanding of PK/PD/efficacy relationships and an ability to utilise preclinical data to inform clinical studies.
- Have demonstrated evidence of knowledge of the global regulatory environment around in vitro diagnostics.
- Previous experience in the design and execution of translational science strategy and plans for oncology projects requiring patient selection.
- Be able to show innovation and creativity; flexibility and adaptability; resilience and ability to make decisions independently
- Preferred applicants will have a Ph.D in a biological science subject such as genetics, pharmacology or molecular biology and experience in biotech or pharma industry.

In return, Redx will offer you the opportunity to work as part of a dynamic team reporting into the CSO and working closely with the Clinical Development team. Redx is an exciting drug discovery and development company where you will get exposure to a broad range of activities and enhance your drug development skills.

The closing date for applications is 25/08/22